Stockreport
Eight-Year Data Confirm Long-Term Durability of Edwards’ RESILIA Tissue
Last edwards lifesciences corporation earnings: 4/23 04:15 pm
Check Earnings Report
US:NYSE Investor Relations: ir.edwards.com
CAIRO--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced new eight-year data showing that patients receiving aortic surgical valves treated with its proprietary RESILIA tissue technology have significantly improved long-term outcomes compared to those receiving non-RESILIA tissue bioprosthetic valves.For more than 65 years, Edwards has been the leader in heart valve innovations. To create a more durable heart valve, Edwards developed the RESILIA tissue technology more than two decades ago. Today, RESILIA tissue is used in a wide range of Edwards’ surgical and transcatheter platforms, including the INSPIRIS RESILIA aortic surgical valve, the KONECT RESILIA aortic surgical valve conduit, the MITRIS RESILIA mitral surgical valve and the SAPIEN 3 Ultra RESILIA transcatheter aortic heart valve. Edwards’ INSPIRIS RESILIA and SAPIEN 3 Ultra RESILIA valves are supported by extensive, long-term clinical evidence which is the result of three decades of innovation and expertis
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | EW | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
EW alerts
EW alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
EW alerts
High impacting Edwards Lifesciences Corporation news events
Weekly update
A roundup of the hottest topics
EW
NEWS
NEWS
- 4 Large-Cap MedTech Stocks to Keep Winning Streaks Alive in 2026 [Yahoo! Finance][Yahoo! Finance]
- Relief Cardiovascular Appoints Harry Rowland as Chairman of the Board [Yahoo! Finance][Yahoo! Finance]
- Edwards Lifesciences (NYSE:EW) was upgraded by analysts at JPMorgan Chase & Co. from a "neutral" rating to an "overweight" rating. They now have a $100.00 price target on the stock, up previously from $90.00.[MarketBeat]
- Edwards Lifesciences (NYSE:EW) was given a new $100.00 price target on by analysts at Wells Fargo & Company.[MarketBeat]
- Edwards Lifesciences to Present at the 44th Annual J.P. Morgan Healthcare Conference[Business Wire]
- More
EW
SEC Filings
SEC Filings
- 12/12/25 - Form 4
- 12/12/25 - Form 4
- 12/12/25 - Form 4
- EW's page on the SEC website
- More